Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 308732, 6 pages
Research Article

Fusion-Expressed CTB Improves Both Systemic and Mucosal T-Cell Responses Elicited by an Intranasal DNA Priming/Intramuscular Recombinant Vaccinia Boosting Regimen

1Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
2Institute of Biomedical Science, Fudan University, Shanghai 200032, China

Received 13 November 2013; Accepted 7 March 2014; Published 1 April 2014

Academic Editor: Diane Williamson

Copyright © 2014 Sugan Qiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Previous study showed that CTB (Cholera toxin subunit B) can be used as a genetic adjuvant to enhance the systemic immune responses. To further investigate whether it can also be used as a genetic adjuvant to improve mucosal immune responses, we constructed DNA and recombinant Tiantan vaccinia (rTTV) vaccines expressing OVA-CTB fusion antigen. Female C57BL/6 mice were immunized with an intranasal DNA priming/intramuscular rTTV boosting regimen. OVA specific T-cell responses were measured by IFN-γ ELISPOT and specific antibody responses were determined by ELISA. Compared to the nonadjuvant group (pSV-OVA intranasal priming/rTTV-OVA intramuscular boosting), pSV-OVA-CTB intranasal priming/rTTV-OVA-CTB intramuscular boosting group significantly improved the magnitudes of T-cell responses at spleen ( SFCs/106 splenocytes versus SFCs/106 splenocytes, ), mesenteric LN ( SFCs/106 lymphocytes versus SFCs/106 lymphocytes, ), draining LNs of respiratory tract ( SFCs/106 lymphocytes versus SFCs/106 lymphocytes, ) and female genital tract ( SFCs/106 lymphocytes versus SFCs/106 lymphocytes, ). These results collectively demonstrated that fusion-expressed CTB could act as a potent adjuvant to improve both systemic and mucosal T-cell responses.